Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Japan Eyes Reduction in Inflation-Linked Bond Buybacks Amid Surging Investor Demand
Israel Defies Trump's Warning, Launches New Strikes on Iran Amid Growing Global Energy Crisis
Iran-Israel War Escalates: Long-Range Missiles, Nuclear Site Strikes, and Global Energy Crisis
Gold Prices Extend Losing Streak, On Track for Worst Weekly Loss Since 1983
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit
Paraguay Central Bank Holds Interest Rate at 5.5% Amid Slowing Growth
Gold Prices Drop Amid Inflation Fears and U.S.-Iran Escalation
GE Vernova and Hitachi's $40 Billion SMR Investment Signals a New Era for U.S. Nuclear Energy
Tesla Eyes $2.9 Billion in Chinese Solar Equipment to Power 100 GW U.S. Manufacturing Push
U.S. Markets Post Fourth Straight Weekly Loss Amid Middle East Escalation
Xiaomi Shares Drop After SU7 Launch as Margin Concerns Weigh on Investors
J.P. Morgan Now Expects Two ECB Rate Hikes Amid Inflation Pressures
Oil Prices Surge Amid Trump's Iran Ultimatum Over Strait of Hormuz
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market
US-Iran War: Trump Eyes Military Exit as Markets React to Potential De-escalation
U.S. Appeals Court Strikes Down FTC Order Against TurboTax "Free" Advertising
EA's $15B Debt Offering Draws $25B in Investor Demand Amid Credit Market Turmoil 



